Skip to search formSkip to main contentSkip to account menu

apremilast

Known as: Apremilastum, Aprémilast, N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (2)

Anti-Inflammatory Agents, Non-SteroidalThalidomide

Narrower (2)

CC 10004Otezla
analogs & derivativesapremilast 28-day starter pack

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3…
Highly Cited
2019
Highly Cited
2019
Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
BACKGROUND The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behçet's… 
Review
2018
Review
2018
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and negative impacts on a patient’s quality… 
Review
2017
Review
2017
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
Apremilast (Otezla®) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice… 
Highly Cited
2016
Highly Cited
2016
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammatory mediator synthesis by… 
Highly Cited
2016
Highly Cited
2016
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Objective To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement… 
Review
2013
Review
2013
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red and silver scaly plaques… 
Highly Cited
2012
Highly Cited
2012
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis
Objectives To evaluate the efficacy and safety of an oral phosphodiesterase 4 inhibitor, apremilast, in treatment of ankylosing… 
Highly Cited
2012
Highly Cited
2012
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
OBJECTIVE To evaluate the efficacy and safety of apremilast, a novel, orally available small molecule that specifically targets… 
Review
2010
Review
2010
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases
Phosphodiesterase 4 (PDE4) is a key enzyme in the degradation of cyclic adenosine monophosphate and is centrally involved in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)